ENDOMETRIAL CARCINOSARCOMA
Clinical trials for ENDOMETRIAL CARCINOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL CARCINOSARCOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL CARCINOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with advanced, recurrent, or metastatic endometrial cancer. The goal was to see if the combo could slow or stop cancer growth. Cabozantinib blocks enzymes that help tumors grow, while nivolumab…
Matched conditions: ENDOMETRIAL CARCINOSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Gene-Guided drug cocktail shows promise for Tough-to-Treat gynaecological cancers
Disease control OngoingThis phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if …
Matched conditions: ENDOMETRIAL CARCINOSARCOMA
Phase: PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug combo aims to shrink endometrial tumors
Disease control OngoingThis phase 2 trial tests whether adding an experimental drug (BMS-986205) to the immunotherapy nivolumab can shrink tumors or prevent cancer from returning in people with recurrent endometrial cancer. About 24 participants will receive the combination. The study compares this com…
Matched conditions: ENDOMETRIAL CARCINOSARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC